Skip Navigation
Print This Page
Share this page: More

Search Results

Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy®) in Patients with Metastatic Melanoma
Protocol Number:
Phase IV
William Sharfman
This research is being done to evaluate two drugs given in sequence (one after the other) including ipilimumab (also known as Yervoy®) and High Dose Interleukin-2 (abbreviated as HD IL-2 and known as Proleukin®) in people with metastatic melanoma. Ipilimumab is approved by the FDA for the treatment ofmetastatic melanoma. HD IL-2 is also FDA-approved for the treatment of metastatic melanoma. Both drugs are approved for the same disease, although the two drugs have not been studied in sequence. The purpose of this research study is to evaluate the response of the disease to ipilimumab and HD IL-2when given in sequence (one after the other). The disease response to the series of drugs will be evaluated four (4) times during the study.
Last Update
10/22/2014 04:03 AM

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers


Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer